Bioscience & Health Care Series: Biopharmaceutical Drug Development February 26, 2008

Exciting research and development in the biomedical sciences is taking place in Oregon's universities including OHSU. Discoveries are being made that could lead to commercialized products in therapeutics, diagnostics and medical devices. But how do you go from research to development to commercialization? There is no single recipe for success but like the preparation and presentation of a fine dinner, you must have all of the ingredients, know how much to use and exactly what role each ingredient plays. It also helps to know what's expected of you from the scientists, the FDA and your investors.

Several years ago, a new drug for treating multiple sclerosis was developed at OHSU. Code named RTL1000, this drug is being administered to MS patients in an FDA approved Phase 1 clinical safety trial. The story of how RTL1000 was taken from laboratory research to an FDA approved clinical trial offers insight into how the process works from the perspective of a startup biopharmaceutical company, Artielle ImmunoTherapeutics, Inc.

Dates/Times: Feb. 26, 2008; 6:00 pm - 8:00 pm
Location: OGI School of Science & Engineering campus, Wilson Clark Center (#3 on campus map), Dining Room
Course Fee: $0
Course Includes: Free seminar and free pizza and soft drinks

Official Website: http://cpd.ogi.edu/courseSpecific.asp?pam=2331